ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results

Circulating tumor DNA (ctDNA) has shown promise in capturing primary resistance to immunotherapy. BR.36 is a multi-center, randomized, ctDNA-directed, phase 2 trial of molecular response-adaptive immuno-chemotherapy for patients with lung cancer. In the first of two independent stages, 50 patients w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature medicine 2023-10, Vol.29 (10), p.2559-2569
Hauptverfasser:	Anagnostou, Valsamo, Ho, Cheryl, Nicholas, Garth, Juergens, Rosalyn Anne, Sacher, Adrian, Fung, Andrea S., Wheatley-Price, Paul, Laurie, Scott A., Levy, Benjamin, Brahmer, Julie R., Balan, Archana, Niknafs, Noushin, Avrutin, Egor, Zhu, Liting, Sausen, Mark, Bradbury, Penelope A., O’Donnell-Tormey, Jill, Gaudreau, Pierre Olivier, Ding, Keyue, Dancey, Janet
Format:	Artikel
Sprache:	eng
Schlagworte:	631/208/212/2301 631/67/1612/1350 692/308/575 692/53/2423 Antibodies, Monoclonal, Humanized Biomedical and Life Sciences Biomedicine Cancer Research Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Chemotherapy Deoxyribonucleic acid DNA Humans Immunotherapy Infectious Diseases Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Metabolic Diseases Molecular Medicine Neurosciences Non-small cell lung carcinoma PD-1 protein Pembrolizumab Progression-Free Survival Small cell lung carcinoma Solid tumors Survival Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!